Ryan Potts

VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father

[Ryan Potts @pottslab]

What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. https://t.co/nfP5GV696s
#mycompnay

[Kenneth Loi @kenjmloi]

Excited to share our discovery of a new programmable RNA-guided DNA-targeting system hiding inside bacteriophages that predates CRISPR.

We call it VIPR (Viral Interference Programmable Repeat), and it uses an entirely new logic to find its targets.

Thread + link below.

[Ryan Potts @pottslab]

Apply now to Amgen’s postbacc program! #mycompany

[William Gibson @wgibson]

What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.

[biorxiv_biochem @biorxiv_biochem]

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small Molecules https://t.co/cbxc0vlcSs #biorxiv_biochem

[bioRxiv Cancer Bio @biorxiv_cancer]

Functional inactivation of the telomerase chaperone TCAB1 primes cells for the activation of ALT in osteosarcoma https://t.co/7WxggjkWin #biorxiv_cancer

[Yuh Min Chook @yuhminchook]

Selinexor is an allosteric degrader: it stabilizes XPO1/CRM1 to expose a cryptic ASB8 E3 ligase site, triggering ubiquitination. Led by Casey Wing, Joyce Fung & Bert Kwanten. #TargetedDegradation #Allostery
https://t.co/aCvxF1UbFa

[bioRxiv Molecular Biology @biorxiv_molbio]

Mapping the latent CRBN-molecular glue degrader interactome https://t.co/5gnmu99iAx #biorxiv_molbio

[bioRxiv Molecular Biology @biorxiv_molbio]

Orthosteric Molecular Glue Inhibits COP9 Signalosome with Substrate-Dependent Potency https://t.co/5qoXusNWSa #biorxiv_molbio

[Kaiyi Jiang @idmjky]

Thrilled to share that I have joined @Amgen
as the inaugural Amgen Science Fellow. I look forward to partnering with colleagues to design next-gen therapeutic by integrating AI/ML with high throughput synthetic biology platforms.
https://t.co/Rbt2ya1rS9

[Itai Yanai @ItaiYanai]

Legend David Baltimore died yesterday. He understood the way things should work: "the real contribution of @MIT is that it doesn't take itself too seriously. It takes ideas seriously, but the people are relatively informal. They are not self-aggrandizing the way academics can be.

[KaelinLab @kaelin_lab]

Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules! https://t.co/OR3BZFzMrx

[Science Magazine @ScienceMagazine]

A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.”

Learn more: https://t.co/seRQqjQVYv

[Ventura's Lab @PPMC_UAB]

Great to see our two in-house developed kinetic stabilizers, Tolcapone and PITB, against transthyretin amyloidoses cited as examples of an emerging therapeutic class: LOCKTACS. https://t.co/a7ZsuNAzMB

[Sally Church @MaverickNY]

Talking of @amgen they also have cool LYMTACs: chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization & degradation https://t.co/EkliolNtOG

[Alex Federation @afederation]

Degradation without E3s?

Cool approach here - molecules that drag membrane proteins into lysosomes for degradation

Might help get around KRASi resistance

[Ryan Potts @pottslab]

@CKRamsoomair @ScienceMagazine Thanks!

[Ryan Potts @pottslab]

What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. https://t.co/nfP5GV696s
#mycompnay

[Ryan Potts @pottslab]

@potthofflab @ScienceMagazine Thanks Matt.

[Amgen 🧪🔬🧬 @Amgen]

Amgen’s LOCKTAC molecular glues are changing how we target disease.

🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.

Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.

🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.

Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.

🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.

Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.

🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.

Read more about how Amgen is working to innovate in this space.

[Ryan Potts @pottslab]

Check out how we repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @nalawansha and team! #mycompany
https://t.co/uCQJYWigsi

[Ryan Potts @pottslab]

🚨New @biorxivpreprint from the @Amgen Induced Proximity group. Here we introduce LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation. 🧵 https://t.co/19IFe2Ib8M